Target validation in silico: does the virtual patient cure the pharma pipeline?

Author： Alkema Wynand   Rullmann Ton   van Elsas Andrea  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.10, Iss.5, 2006-10, pp. : 635-638

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

In silico analysis of antifungal peptides

By Soltani Saeed   Keymanesh Keykhosrow   Sardari Soroush  

Expert Opinion on Drug Discovery, Vol. 2, Iss. 6, 2007-06 ,pp. : 837-847

Informa Healthcare

Access to resources Recommend Favorite

Development of drugs for Epstein–Barr virus using high-throughput in silico virtual screening

By Li Ning   Thompson Scott   Jiang Hualiang   Lieberman Paul M   Luo Cheng  

Expert Opinion on Drug Discovery, Vol. 5, Iss. 12, 2010-12 ,pp. : 1189-1203

Informa Healthcare

Access to resources Recommend Favorite

Strategies for the generation, validation and application of in silico ADMET models in lead generation and optimization

By Gleeson Matthew Paul   Montanari Dino  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 8, Iss. 11, 2012-11 ,pp. : 1435-1446

Informa Healthcare

Access to resources Recommend Favorite

Design and in silico screening of inhibitors of the cholera toxin

By Zhang Guangtao  

Expert Opinion on Drug Discovery, Vol. 4, Iss. 9, 2009-09 ,pp. : 923-938

Informa Healthcare

Access to resources Recommend Favorite

In silico fragment-based drug design

By Konteatis Zenon D  

Expert Opinion on Drug Discovery, Vol. 5, Iss. 11, 2010-11 ,pp. : 1047-1065

Informa Healthcare

Access to resources Recommend Favorite